Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

2cureX - Updated report from Mangold

Planlagt Fastgjort Låst Flyttet Debatforum
0 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #1

    Mangold Fondkommission AB published an updated Analyst Report on
    2cureX

    Copenhagen - Oct 29, 2021 - Mangold Fondkommission AB issued today an updated Equity Analyst Report on 2cureX (Insight.Mangold (https://mangold.se/bolag/2curex/)).

    The report is in Swedish at 2cureX's web-site (Analyst Coverage).

    For more information about 2cureX:

    Fernando Andreu, Chief Executive Officer
    E-mail: [email protected]
    Telephone: +45 2279 5399
    www.2curex.com

    About 2cureX

    2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

    The first IndiTreat® test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

    According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

    The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

    Certified Adviser: Redeye AB, +46 8 121 576 90, [email protected]

    ProInvestor.com modtager betaling fra 2cureX for digital IR.

    98161_2curex_update_2021_10_29.pdf

    1 Reply Last reply
    0

    Hello! It looks like you're interested in this conversation, but you don't have an account yet.

    Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

    With your input, this post could be even better 💗

    Tilmeld Log ind

    • Log ind

    • Har du ikke en konto? Tilmeld

    • Login or register to search.
    • First post
      Last post
    0
    • Debatforum
    • Seneste
    • Populære
    • Bruger